JAGUAR HEALTH, INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
JAGUAR HEALTH, INC. (JAGX) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $614.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-19
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $614.00K.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $675.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $735.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $801.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $614.00K 10-Q · filed 2026-08-19 |
| 2026-03-31 | $675.00K 10-Q · filed 2026-05-20 |
| 2025-12-31 | $735.00K 10-Q · filed 2026-08-19 |
| 2025-09-30 | $801.00K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $867.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $929.00K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $624.00K 10-K · filed 2026-04-07 |
| 2024-09-30 | $668.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $722.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $781.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $828.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $109.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $143.00K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $195.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $231.00K 10-K · filed 2023-03-24 |
| 2022-09-30 | $280.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $336.00K 10-Q · filed 2022-08-22 |
| 2022-03-31 | $389.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $445.00K 10-Q · filed 2022-11-14 |
| 2021-09-30 | $396.00K 10-Q · filed 2021-11-17 |
| 2021-06-30 | $456.00K 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |